A Phase 1B Study of Cabozantinib and Nivolumab Immunotherapy With Radiation Therapy to Treat Kidney Cancer That Spread to the Brain


Full Title

A phase Ib study of the safety of concurrent cabozantinib and nivolumab with radiation therapy for brain metastases in patients with metastatic renal cell carcinoma


Researchers want to see if giving two drugs with radiation therapy is safe and helps people with advanced kidney cancer. The people in this study have renal cell carcinoma that spread to the brain. The two drugs are cabozantinib and nivolumab.

Cabozantinib blocks the growth of blood vessels that tumors need to grow and spread. It is taken orally (by mouth). Nivolumab is a type of immunotherapy. It boosts the power of the immune system to find and kill cancer cells. Nivolumab is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have renal cell cancer that spread to the brain.
  • Plan to have radiation therapy to treat brain metastases.
  • Not have had prior cabozantinib treatment.
  • Have completed any prior radiation therapy to the brain at least 4 weeks before getting the study treatment.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Ritesh Kotecha’s office at 646-422-4839.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID